Longevity Health Holdings, Inc. competitors & alternatives

Oral BiolifeHealthcareUnited States

65% match

Healthcare

Oral Biolife is an innovative biotech company that develops first-in-class piezoelectric therapies converting mechanical force into bone regeneration. Headquartered in Bethlehem, Pennsylvania, the firm is transforming periodontal treatments with products such as Ambrilux Dental Gel.

Organogenesis Holdings Inc.ORGO · BiotechCanton, United States

66% matchPublic

Biotech

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

OssiFi IncBiotechnologyUnited States

64% matchPrivate

Biotechnology

OssiFi Inc. is a bone biology company founded in 2014 and located in Overland Park, Kansas. It focuses on developing therapies and medical devices to meet needs in neurogenic conditions.

Kuros Biosciences AGKURN · Biotechnology / MedtechSchlieren, Switzerland

63% matchPublic

Biotechnology / Medtech

Kuros Biosciences AG is a Swiss-headquartered biotech company, listed on the SIX Swiss Exchange. The company focuses on growing bone with products like MagnetOs Bone Graft.

Biotechnology

Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to cell therapy throughout Japan. The company offers various cell therapy kits and continuously advances cellular treatment technologies through ongoing research and development. Its active development pipeline includes ECCI-50, designed for the treatment of male stress urinary incontinence and hepatic cirrhosis, and Cyt-006, formulated to prevent postoperative adhesion after primary rectal cancer surgery. Additionally, Cytori conducts extensive clinical trials and investigations into cell-based therapies for a wide array of conditions and applications, such as the repair of anterior cruciate ligaments and bones, burn scar remediation, chronic wound healing, critical limb ischemia, treatment of anal and Crohn's disease fistulas, and erectile dysfunction. Beyond its primary biotechnological focus, the company also participates in the real estate sector, encompassing investment, ownership, development, leasing, and management of properties and hotels, as well as providing real estate brokerage services.

Biotech

Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and commercialization of biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various other international regions. A comprehensive product portfolio addresses several key medical disciplines. Within ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. Orthopedics products encompass sodium hyaluronate injections and medical chitosan. For wound repair, it manufactures recombinant human epidermal growth factor, effective in treating burn wounds, residual wounds, donor site post-traumatic wounds, and both fresh and chronic ulcerations. Additionally, the company develops anti-adhesion materials, including medical sodium hyaluronate gel and medical chitosan, as well as hemostatic solutions such as collagen sponges and porcine fibrin sealants. Beyond its therapeutic offerings, Shanghai Haohai maintains a significant presence in the medical aesthetics market. This segment features a range of hyaluronic acid (HA) dermal fillers: Matrifill, positioned as a first-generation mono-phase injectable HA gel; Janlane, a second-generation filler engineered for dynamic application; and Hyalumatrix, a third-generation product providing precise aesthetic embellishment. Its aesthetic portfolio is further complemented by radio frequency devices and laser equipment. Furthermore, the company actively engages in the research and development of biological engineering and pharmaceutical products, extending services such as technology transfer and consultation. It also conducts investment and trading operations. Established in 2007, the entity initially traded as Haohai Limited before officially adopting the name Shanghai Haohai Biological Technology Co., Ltd. in 2010. Its corporate headquarters are based in Shanghai, China.

Biotech

Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal system and various other organs, which may stem from cancer, trauma, or congenital defects. The company's primary experimental therapy, the Cellspan Esophageal Implant, aims to treat severe esophageal disease. Beyond this, its development pipeline encompasses organ-regeneration technologies designed for the repair or replacement of damaged or diseased organs. This includes product candidates targeting diverse esophageal ailments—such as those caused by traumatic injury, caustic burns, or tissue damage from chemoradiation therapy, as well as birth defects—and solutions for colon and uterine wound reconstruction. Additionally, the company offers consumer health products, including dietary supplements, focusing on personal wellness. Founded in 2009 and headquartered in Holliston, Massachusetts, the company operated as Biostage, Inc. until its rebranding to Harvard Apparatus Regenerative Technology Inc. in July 2023.

Biotech

Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.

Eterna RegenerativesBiotechnologyUnited Kingdom

63% match

Biotechnology

Eterna Regeneratives develops regenerative biomaterials and protein-derived scaffolds designed for mineralisation and tissue regeneration. The company's initial applications focus on oral health and enamel repair through professional consumer dental care formats, as well as bone regeneration for orthopaedic and bone grafting uses.

ORTHOCELL LIMITEDPharmaceuticals, Biotechnology & Life SciencesMurdoch, Australia

63% match

Pharmaceuticals, Biotechnology & Life Sciences

Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.

Biotech

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Regenity BiosciencesBiotechnologyUnited States

63% match

Biotechnology

Regenity Biosciences is a medical device supplier and biotechnology company headquartered in Paramus, New Jersey, specializing in regenerative medicine and collagen matrix products with nearly 30 years of history.